TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03432221

Intervention type: DRUG
Intervention: Desvenlafaxine
Description: Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
Study: NCT01509391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: keyhole-limpet hemocyanin
Description: Subcutaneous administration keyhole-limpet hemocyanin
Study: NCT04238195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo
Description: Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400mg
Description: Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment C: Subjects receive TBPM-PI-HBr matching placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment C: Subjects receive TBPM-PI-HBr matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment B: Subjects receive TBPM-PI-HBr.
Study: NCT03280615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil will be the placebo comparator for omega 3 fatty acids supplement
Study: NCT03052257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational - glaucoma
Description: Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose monitoring and reminder
Description: Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational - general
Description: The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose monitoring
Description: Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened.
Study: NCT03550326

Intervention type: PROCEDURE
Intervention: airway management
Description: patients will be intubated or will be placed an airway device
Study: NCT01615003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule
Description: Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xuesaitong soft capsule Placebo
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Study: NCT04499508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optima Coil System
Description: Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
Study: NCT02821793

Intervention type: OTHER
Intervention: Consultation, evaluation questionnaire
Description: Consultation, evaluation questionnaire

Intervention type: OTHER
Intervention: Geriatric consultation, evaluation questionnaire
Description: Geriatric consultation, evaluation questionnaire
Study: NCT04288076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP Titrated Mechanical Ventilation
Description: Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
Study: NCT00286533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination (implant stability, gingiva condition, etc.)
Description: Clinical examination (implant stability, gingiva condition, etc.) to follow

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires are used.
Study: NCT04152356

Intervention type: DRUG
Intervention: PD-1
Description: PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.

Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
Study: NCT01595256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscular strength
Description: 12-week moderate intensity walking program
Study: NCT03699839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine
Description: The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Description: The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intramuscular influenza vaccine
Description: The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
Study: NCT03137394

Intervention type: OTHER
Intervention: Observation
Description: Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.

Intervention type: OTHER
Intervention: Observation
Description: Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
Study: NCT04911101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excision with 7G needle
Description: Vacuum-assisted excision using a biopsy needle with two alternative dimensions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excision with 10G needle
Description: Vacuum-assisted excision using a biopsy needle with two alternative dimensions
Study: NCT03061968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
Study: NCT02145767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03465852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChiCAS
Description: Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ChiCAS
Description: Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
Study: NCT02692053

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling
Description: additional blood sampling (volume: 18 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: additional blood sampling (volume: 18 mL)
Study: NCT01220752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion boost
Description: 8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
Study: NCT01198444

Intervention type: DRUG
Intervention: EE/DRSP (Yasmin Product Family)
Description: One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
Study: NCT03692910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo capsule
Study: NCT03611400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
Study: NCT00509873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.5% eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study: NCT00193674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: 20 mg/day, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01883245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: 2 milliampere real direct current stimulation for 20 minutes daily for 5 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: 2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
Study: NCT03253198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposome
Description: an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
Study: NCT01583582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis Refined Peptide Concentrate
Description: 1200 mg per os, once a day, 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis Refined Peptide Concentrate
Description: 600 mg per os, twice a day, 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Marealis Refined Peptide Concentrate
Description: 0 mg per os, daily, 8 weeks
Study: NCT04066556

Intervention type: OTHER
Intervention: Brain CT imaging
Description: The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments.
Study: NCT01914445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Carmine
Description: Oral administration of Indigo Carmine prior to colonoscopy
Study: NCT02538666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01651182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No tranexamic acid
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT00687154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scatter Laser Photocoagulation in 1 Sitting
Description: 1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scatter Laser Photocoagulation in 4 Sittings
Description: 4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
Study: NCT02844582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT02416908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study: NCT02369679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precast Adjustable Compression Wrap (Circaid)
Description: A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
Study: NCT02416908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Study: NCT01807507

Intervention type: DEVICE
Intervention: VeinViewer
Description: VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
Study: NCT00959296

Intervention type: DEVICE
Intervention: Various
Description: Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
Study: NCT00763685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg, paracetamol 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg, paracetamol 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg, paracetamol 1 g
Study: NCT00298610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous Artesunate (2.4 mg/kg) once a day for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
Study: NCT03566537

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study: NCT01585129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postpartum Antibiotics
Description: Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No postpartum antibiotics
Description: Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
Study: NCT03614429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel will be prepared according to an international product Instillagel®
Description: Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not.
Study: NCT02369679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multilayer Compression Bandages
Description: A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
Study: NCT00558480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A placebo
Description: Vitamin A placebo at enrollment, 3 and 6 months
Study: NCT00337298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 1 (5mg) tablet daily, given 14 days totally before measure of outcome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 10 mg given daily for 14 days and then outcome was measured.
Study: NCT01214434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promiseb Topical Cream
Description: topical non steroidal cream, twice daily